Flora Growth Corp. (FLGC) Reports Q2 Loss, Tops Revenue Estimates

Core Insights - Flora Growth Corp. reported a quarterly loss of $0.11 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, marking an earnings surprise of -83.33% [1] - The company generated revenues of $14.8 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 25.71%, but down from $15.68 million year-over-year [2] - Flora Growth shares have declined approximately 42.9% year-to-date, contrasting with the S&P 500's gain of 7.8% [3] Financial Performance - Over the last four quarters, Flora Growth has consistently failed to meet consensus EPS estimates [2] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $12.52 million, and for the current fiscal year, it is -$0.40 on revenues of $47.63 million [7] Industry Context - The Medical - Products industry, to which Flora Growth belongs, is currently ranked in the bottom 26% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Flora Growth's stock may be influenced by the overall outlook of the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [8]